PharmAust Limited announced a protocol deviation in its MND trial to elevate a Cohort 1 patient to Cohort 2. With the patient being stable, the Principal Investigator has recommended that the patient be elevated to Cohort 2 and the associated increase in MPL dosage. The patient is later expected to be moved to Cohort 4 with the other Cohort 2 patients, subject to Safety Committee approval.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.215 AUD | -8.51% | +16.22% | +86.96% |
05-31 | PharmAust Reappoints CEO | MT |
05-17 | PharmAust Appoints Nonexecutive Chair; Shares Up 3% | MT |
1st Jan change | Capi. | |
---|---|---|
+86.96% | 53.95M | |
+42.69% | 750B | |
+34.11% | 606B | |
-6.87% | 356B | |
+18.74% | 326B | |
+6.76% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.64% | 167B |
- Stock Market
- Equities
- PAA Stock
- News PharmAust Limited
- Pharmaust Limited Announces A Protocol Deviation in Its MND Trial to Elevate A Cohort 1 Patient to Cohort 2